Gerresheimer Reports Strong Q1 Growth Post-Bormioli Pharma Acquisition

Gerresheimer AG, a key player in the pharma, biotech, and cosmetics markets, recorded an 11.6% revenue increase in Q1 2025, reaching EUR 520.1 million, largely due to its acquisition of Bormioli Pharma. The adjusted EBITDA rose by 13.1% to EUR 91.5 million. However, organic development saw a decline, with a 6.5% drop in revenues and a 9.3% decline in adjusted EBITDA compared to Q1 2024, influenced by a shift in syringe business revenues.

The Plastics & Devices Division showed a 14.0% revenue increase, but a 3.3% organic revenue decline was attributed to the syringe business shift. Meanwhile, the Primary Packaging Glass Division expanded margins due to a product mix change, with revenues rising by 9.0% and adjusted EBITDA growing by 15.4%.

Despite these mixed results, Gerresheimer reaffirms its 2025 guidance, forecasting an organic revenue growth of 3-5% and an enhanced adjusted EBITDA margin of around 22%, betting on strong demand for high-value biologics solutions and new production lines.